https://aztiq.com/media/ weekly 0.7 2022-04-03T20:01:29.000Z https://aztiq.com/person/jon-vi%C3%B0ar-gu%C3%B0jonsson weekly 0.7 2022-04-04T15:31:13.000Z https://aztiq.com/person/kristin-hulda-sverrisdottir weekly 0.7 2022-04-05T14:49:10.000Z https://aztiq.com/investment/alvogen-cee weekly 0.7 2022-04-20T11:19:08.000Z https://aztiq.com/person/eunsun-choi weekly 0.7 2022-04-27T11:21:16.000Z https://aztiq.com/about-aztiq weekly 0.7 2022-04-27T11:45:58.000Z https://aztiq.com/investment/lotus weekly 0.7 2022-04-27T14:26:56.000Z https://aztiq.com/investment/almatica weekly 0.7 2022-04-27T14:30:57.000Z https://aztiq.com/investment/almaject weekly 0.7 2022-04-27T14:32:01.000Z https://aztiq.com/investment/alvogen weekly 0.7 2022-04-27T14:42:29.000Z https://aztiq.com/our-companies weekly 0.7 2022-05-07T09:34:55.000Z https://aztiq.com/person/david-olafsson weekly 0.7 2022-05-09T10:57:41.000Z https://aztiq.com/ weekly 0.7 2022-05-09T17:01:18.000Z https://aztiq.com/person/arni-hardarson weekly 0.7 2022-05-13T09:57:37.000Z https://aztiq.com/media/one-of-the-highest-grossing-biologic-medicines weekly 0.5 2022-05-31T12:51:20.000Z https://aztiq.com/media/lotus-reports-solid-performance-in-first-quarter-of weekly 0.5 2022-06-01T10:55:47.000Z https://aztiq.com/media/positive-results-from-a-pharmacokinetic-similarity weekly 0.5 2022-06-01T10:56:45.000Z https://aztiq.com/media/alvotech-global-biotech-company-and-oaktree-acquisition weekly 0.5 2022-06-01T11:00:45.000Z https://aztiq.com/media/robert-wessman-led-aztiq-completes-500-million-transaction weekly 0.5 2022-06-01T11:01:27.000Z https://aztiq.com/media/alvotech-and-fuji-pharma-expand-partnership-for-additional weekly 0.5 2022-06-01T11:02:13.000Z https://aztiq.com/media/avt02-approved-for-use-in-european-union weekly 0.5 2022-06-01T11:02:58.000Z https://aztiq.com/media/fda-accepts-alvotechs-bla-supporting-interchangeability weekly 0.5 2022-06-01T11:04:13.000Z https://aztiq.com/media/a-powerful-investment-alliance-of-aztiq-and-innobic weekly 0.5 2022-06-01T11:04:45.000Z https://aztiq.com/media/alvotech-and-oaktree-acquisition-corp.-ii-announce weekly 0.5 2022-06-01T11:05:40.000Z https://aztiq.com/media/newly-issued-share-equity-in-alvogen-us weekly 0.5 2022-06-01T11:06:28.000Z https://aztiq.com/media/alvogen-and-sister-company-alvotech-donate-100-thousand weekly 0.5 2022-06-01T11:07:18.000Z https://aztiq.com/media/adalvo-announces-successful-pivotal-be-outcome-of-apremilast weekly 0.5 2022-06-01T11:08:19.000Z https://aztiq.com/media/lotus-achieves-another-record-high-eps-for-fy2021 weekly 0.5 2022-06-01T11:08:48.000Z https://aztiq.com/media/ptt-invests-us50-million-in-lotus weekly 0.5 2022-06-01T11:09:22.000Z https://aztiq.com/media/robert-wessman-inaugurates-new-london-offices weekly 0.5 2022-06-01T11:09:49.000Z https://aztiq.com/media/aztiq-buys-17-stake-in-alvogen-us weekly 0.5 2022-06-01T11:10:24.000Z https://aztiq.com/media/alvotech-resolves-u.s.-patent-and-trade-secret-disputes weekly 0.5 2022-06-01T11:11:13.000Z https://aztiq.com/media/announce-shareholder-approval-of-business-combination weekly 0.5 2022-06-08T08:01:42.000Z https://aztiq.com/media/alvotech-debuts-on-nasdaq-first-north-growth-market weekly 0.5 2022-06-23T10:16:11.000Z https://aztiq.com/media/expected-to-be-the-largest-debut-by-an-icelandic-company weekly 0.5 2022-06-23T10:27:55.000Z https://aztiq.com/person/danny-major weekly 0.7 2022-07-04T18:08:27.000Z https://aztiq.com/media/a-proposed-biosimilar-for-eylea weekly 0.5 2022-07-27T14:56:19.000Z https://aztiq.com/media/alvotech-expands-its-board-of-directors weekly 0.5 2022-07-27T15:24:53.000Z https://aztiq.com/media/alvotech-initiates-a-pharmacokinetic-study-for-avt03 weekly 0.5 2022-07-27T15:28:52.000Z https://aztiq.com/media/alvotech-nasdaq-alvo-announced-that-its-board-of weekly 0.5 2022-08-25T10:04:49.000Z https://aztiq.com/media/alvotech-initiates-confirmatory-patient-study-for-avt03 weekly 0.5 2022-08-25T10:54:36.000Z https://aztiq.com/media/adalvo-announces-dcp-approval-for-enzalutamide-soft weekly 0.5 2022-08-25T11:49:23.000Z https://aztiq.com/media/adalvo-announces-dcp-approval-for-dimethyl-fumarate weekly 0.5 2022-08-25T12:03:41.000Z https://aztiq.com/media/adalvo-acquires-its-first-branded-product-onsolis weekly 0.5 2022-08-25T13:46:37.000Z https://aztiq.com/media/lotus-increases-equity-stake-in-alvogen-us weekly 0.5 2022-08-25T14:51:58.000Z https://aztiq.com/media/stronger-board-of-directors-to-accelerate-growth-and weekly 0.5 2022-08-25T15:13:13.000Z https://aztiq.com/media/lotus-announced-that-its-consolidated-sales-for-june weekly 0.5 2022-08-29T12:28:52.000Z https://aztiq.com/media/lotus-monthly-sales-report-for-july-2022 weekly 0.5 2022-08-29T12:55:21.000Z https://aztiq.com/media/lotus-and-fuji-pharma-submitted-1st-co-developed-high weekly 0.5 2022-08-29T13:06:41.000Z https://aztiq.com/media/lotus-receives-tentative-approval-for-midostaurin-anda weekly 0.5 2022-08-29T13:25:06.000Z https://aztiq.com/media/adalvo-announces-successful-dcp-closure-for-fulvestrant weekly 0.5 2022-08-29T14:29:02.000Z https://aztiq.com/media/adalvo-advances-in-the-pain-domain-offering-an-extensive weekly 0.5 2022-08-29T14:29:48.000Z https://aztiq.com/media/alvotech-announces-corporate-sustainability-participation weekly 0.5 2022-08-30T10:32:27.000Z https://aztiq.com/media/secured-funding-of-approximately-185-million-in-gross weekly 0.5 2022-09-02T11:44:47.000Z https://aztiq.com/media/lotus-management-expects-that-the-launch-of-lenalidomide weekly 0.5 2022-09-09T09:45:02.000Z https://aztiq.com/media/alvotech-appoints-sarah-tanksley-as-chief-quality-officer weekly 0.5 2022-10-12T16:39:07.000Z https://aztiq.com/media/alvotechs-partner-submits-application-for-marketing weekly 0.5 2022-10-19T12:11:39.000Z https://aztiq.com/media/alvotech-and-jamp-pharma-expand-exclusive-partnership weekly 0.5 2022-10-19T12:16:31.000Z https://aztiq.com/media/adalvo-and-hikma-sign-exclusive-licensing-agreement weekly 0.5 2022-10-19T12:24:07.000Z https://aztiq.com/media/this-exclusive-partnership-agreement-includes-a-basket weekly 0.5 2022-10-19T12:44:43.000Z https://aztiq.com/media/alvotech-announces-australian-marketing-authorization weekly 0.5 2022-11-15T09:38:23.000Z https://aztiq.com/media/taipei-taiwan10-november-2022--lotus-pharmaceutical weekly 0.5 2022-11-15T10:40:03.000Z https://aztiq.com/media/alvotech-secures-financing-facilities-of-approximately weekly 0.5 2022-11-16T13:56:02.000Z https://aztiq.com/media/alvotech-announces-changes-to-its-leadership-team weekly 0.5 2022-12-02T12:22:49.000Z https://aztiq.com/media/alvotech-shares-start-trading-on-nasdaq-iceland-main weekly 0.5 2022-12-08T08:52:18.000Z https://aztiq.com/media/alvotech-completes-70-million-private-placement weekly 0.5 2022-12-20T13:45:01.000Z https://aztiq.com/media/alvotech-and-stada-broaden-access-to-hukyndra-adalimumab weekly 0.5 2022-12-20T13:50:32.000Z https://aztiq.com/media/update-on-u.s.-regulatory-status-of-avt02-alvotechs weekly 0.5 2022-12-22T10:28:17.000Z https://aztiq.com/media/lotus-monthly-sales-report-for-november-2022 weekly 0.5 2022-12-22T10:37:26.000Z https://aztiq.com/media/lotus-acquires-alimta-pemetrexed-in-taiwan-from weekly 0.5 2022-12-22T10:45:35.000Z https://aztiq.com/media/alvotech-and-teva-announce-acceptance-of-u.s.-biologics weekly 0.5 2023-01-09T11:42:10.000Z https://aztiq.com/media/lotus-obtained-another-exclusive-right-of-cancer-injectable weekly 0.5 2023-01-09T11:49:19.000Z https://aztiq.com/media/alvotech-initiates-pharmacokinetic-study-for-avt05 weekly 0.5 2023-01-12T14:09:46.000Z https://aztiq.com/media/lotus-ends-2022-on-a-strong-note-with-full-year-revenue weekly 0.5 2023-01-16T09:38:00.000Z https://aztiq.com/media/lotus-obtains-tentative-approval-for-nintedanib-anda weekly 0.5 2023-01-16T10:02:26.000Z https://aztiq.com/media/alvotech-completes-137-million-private-share-placement weekly 0.5 2023-01-25T12:00:04.000Z https://aztiq.com/media/alvotech-and-bioventure-announce-approval-of-avt02 weekly 0.5 2023-01-25T12:20:50.000Z https://aztiq.com/media/adalvo-signs-licensing-deal-with-ms-pharma-for-solifenacin weekly 0.5 2023-01-25T13:11:23.000Z https://aztiq.com/media/adalvo-and-aristo-pharma-sign-licensing--supply-agreement weekly 0.5 2023-01-25T13:11:56.000Z https://aztiq.com/media/adalvo-and-frontier-biopharmazdravlje-sign-licensing weekly 0.5 2023-01-25T13:15:34.000Z https://aztiq.com/media/zentiva-extends-its-collaboration-with-adalvo-and-strengthens weekly 0.5 2023-01-25T13:21:54.000Z https://aztiq.com/media/adalvo-and-stada-extend-their-strategic-partnership weekly 0.5 2023-01-25T13:28:07.000Z https://aztiq.com/media/collaboration-with-adalvo-is-another-step-forward-in weekly 0.5 2023-01-25T13:49:57.000Z https://aztiq.com/media/alvotech-and-fuji-pharma-expand-partnership-adding weekly 0.5 2023-01-25T15:21:36.000Z https://aztiq.com/contact weekly 0.7 2023-02-14T13:46:39.000Z https://aztiq.com/media/ema-confirms-acceptance-of-application-for-avt04-a weekly 0.5 2023-02-21T12:52:41.000Z https://aztiq.com/media/lotus-reported-unaudited-january-revenues-of-nt2007 weekly 0.5 2023-02-21T12:56:49.000Z https://aztiq.com/media/alvotech-announces-changes-to-its-leadership-team1 weekly 0.5 2023-02-21T13:35:52.000Z https://aztiq.com/investment/alvotech weekly 0.7 2023-06-27T11:29:37.000Z https://aztiq.com/media/aztiq-and-innobic-announce-pricing-of-secondary-sale weekly 0.5 2023-07-19T10:26:02.000Z https://aztiq.com/media/nrx-pharmaceuticals-lotus-pharmaceuticals-and-alvogen weekly 0.5 2023-07-19T10:31:33.000Z https://aztiq.com/media/mitsui-acquires-convertible-bonds-issued-by-alvotech weekly 0.5 2023-07-19T10:42:48.000Z https://aztiq.com/team weekly 0.7 2024-03-05T12:48:19.000Z https://aztiq.com/person/robert-wessman weekly 0.7 2025-03-04T16:01:43.000Z https://aztiq.com/media/alvogen-refinancing weekly 0.5 2025-03-10T07:29:30.000Z https://aztiq.com/media/aztiq-sells-adalvo weekly 0.5 2025-07-18T08:39:55.000Z